louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05073848: Relationships Between Physical Activity and Different Measures of Fatigue in Cancer Survivors
Official title: Relationships Between Physical Activity and Different Measures of Fatigue in Cancer Survivors
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cancer Remission
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2021-10-12
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We will enroll 50-150 cancer survivors participating in the BfitBwell Cancer Exercise Program. As this is a non-invasive, exploratory observational investigation, there are minimal inclusion and exclusion criteria.

Brief summary: This is an investigation of possible relationships between daily physical activity (PA) and different measurements of fatigue in cancer survivors participating in a cancer exercise program.

Detailed description: This is an investigation of possible relationships between daily physical activity (PA) and different measurements of fatigue in cancer survivors participating in a cancer exercise program. Results will inform exercise prescription and timing to best reduce fatigue, as well as methodology for measuring fatigue. Participants will answer several daily questions on fatigue using a smartphone application during the 3 month exercise program and wear a PA monitor for 10 days during the first month and last month of the program.

Eligibility criteria: Inclusion Criteria:

* Be an active participant in the BfitBwell Cancer Exercise Program
* Criteria for this program include:
* Adult (\>= 18 years old)
* Being a patient seen at the University of Colorado Cancer Center
* Currently receiving cancer therapy or be within 6 months of completing cancer therapy
* Have a signed physician clearance form to participate in an exercise program
* Have a smartphone (necessary for the EMA assessments)
* A score of 48 or less on the FACIT-Fatigue (completed during the initial BfitBwell Program assessment)
* The minimally important difference of the FACIT-Fatigue is 3 points, suggesting that a score of at most 48 indicates the presence of CRF and allows for meaningful change in both directions.

Exclusion Criteria:

* None

Primary outcomes:
measure: 10-point Fatigue Scale, Day
timeFrame: 3 months
measure: Physical Activity measure by Actigraph device
timeFrame: 3 months
Secondary outcomes:
measure: Physical assessment measures from BfitBwell Program
timeFrame: 3 months
Other outcomes:
measure: Response Rate to EMA assessments
timeFrame: 3 months
Locations:
city: Aurora
country: United States
facility: University of Colorado Cancer Center
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Ryan Marker, PhD, PT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00766948: The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry
Official title: The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Parkinson's Disease
Lead sponsor: Scripps Translational Science Institute
Sponsor class: OTHER
Collaborators: name: Scripps Health
name: The Scripps Research Institute
First posted: 2008-10-06
Enrollment: 100
Sex: ALL
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients 30 years of age or older with the diagnosis idiopathic Parkinson's disease

Brief summary: By creating a neurogenebank from Parkinson's disease patients' blood donations we will ultimately be able to define genes for Parkinson's disease and other neurological conditions.


Eligibility criteria: Inclusion Criteria:

* Is age 30 years or older at the time of onset of Parkinson's
* Has been diagnosed with idiopathic Parkinson's Disease by a Scripps Neurologist
* Is reliable, cooperative and willing to comply with all protocol-specified procedures and/or sub-study if consented or have legal representative/guardian willing to do so
* Able to understand and grant informed consent or have a legal representative/ guardian who is able to do so

Exclusion Criteria:

* Patient has been previously enrolled in The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry
* If a blood draw would be contraindicated for any reason
* Has a significant chronic medical condition (i.e. CVA, hepatic encephalopathy) which, in the investigator's option, may interfere with the patient's optimal participation in the study
* Treatment with any investigational agents or devices within 30 days preceding enrollment in the study
* Has undergone ECT within 90 days preceding enrollment in the study

Primary outcomes:
measure: Neurogenetic databank
timeFrame: Study completion
Secondary outcomes:
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: Scripps Clinic, Torrey Pines
state: California
city: La Jolla
country: United States
facility: Scripps Translational Science Institute
state: California
city: La Jolla
country: United States
facility: The Scripps Research Institute
state: California
Study officials:
affiliation: Scripps Translational Science Institute and Genomic Medicine
name: Cinnamon Bloss, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06787248: Real-time Neurofeedback Training of the Medial Prefrontal Cortex Based on Positive Episodic Future Thinking
Official title: Self-regulation of the MPFC Using Rt-fMRI NF Training to Enhance Positive Anticipation for Future Events
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Healthy
Neurofeedback
Keywords: real-time neurofeedback
episodic future thinking
mPFC
Lead sponsor: University of Electronic Science and Technology of China
Sponsor class: OTHER
First posted: 2025-01-22
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Randomized active-sham controlled between-subject real-time fMRI neurofeedback trial aiming to modulate activity in the medial prefrontal cortex (mPFC) to improve subjective positive anticipation.

Detailed description: A randomized double-blind sham-controlled between-subject design using real-time fMRI neurofeedback. In a randomized order, a total of 60 healthy subjects will be recruited and assigned (1) experimental group (EG; N=30), which receives real neurofeedback from the left medial prefrontal cortex (mPFC), or (2) control group (CG; N=30) which receives sham neurofeedback from the primary motor cortex (M1). Neurofeedback training consists of 1 baseline session without feedback, 4 training sessions with real-time feedback, and and 1 transfer session without feedback. Resting state fMRI will be employed to explore neural effects. Objectives are to determine (1) if subjects in the neurofeedback (NF) group can gain volitional control over the mPFC activation using positive episodic regulation strategy, (2) whether successful increased modulation of the mPFC could enhance positive anticipation for future events and motivation (using the Effort-Expenditure for Reward Task, EEfRT).

Eligibility criteria: Inclusion Criteria:

* Healthy subjects without any past or present psychiatric or neurological disorders

Exclusion Criteria:

* History of brain injury
* Psychiatric or Neurological Disorder
* Contraindications for MRI
* Regular use of psychotropic substances (medication, drugs)

Primary outcomes:
measure: Neural activity of the medial prefrontal cortex (mPFC) based on blood oxygen level-dependent (BOLD) signal
timeFrame: 1 hour
Secondary outcomes:
measure: Training-related changes in anticipated pleasure
timeFrame: 1 hour
measure: Training-related changes in motivational effort
timeFrame: 1 hour
Other outcomes:
Locations:
city: Chengdu
country: China
facility: University of Electronic Science and Technology of China(UESTC)
state: Sichuan
Study officials:
References:
Clinical trial NCT05705648: Nutritional Management of Post COVID-19 Cognitive Symptoms
Official title: Nutritional Management of Post COVID-19 Cognitive Symptoms
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Long COVID
Keywords: brain fog; confusion; memory loss; functional decline
Lead sponsor: University of Alberta
Sponsor class: OTHER
First posted: 2023-01-31
Enrollment: 100
Sex: ALL
Minimum age (years): 22
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomised placebo-controlled clinical trial
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn about in brain "fog" complaints associated with long-COVID in people aged 22-50-years. The main questions it aims to answer are:

* the natural course of brain "fog" complaints
* the effect, if any of supplemental dietary oil on brain "fog" complaints Participants will be asked to undergo some brain testing (X-rays and questions. Treatments they'll be given will be one of two supplemental oils to consume daily.

Researchers will compare outcomes in the two different oil groups to see if it has any effect on brain "fog" complaints.

Detailed description: Randomized placebo-control clinical trial comparing two types of nutritional oil and evaluating the impact, if any, on subjective complaints of long-COVID cognitive changes.

Eligibility criteria: Inclusion Criteria:

* confirmed COVID infection, at least 3 months previously, with ongoing cognitive complaints
* all other medical conditions stable, and on stable doses of medications (if required)

Exclusion Criteria:

* COVID infection not confirmed by PCR or Rapid test
* unable to speak English
* pre-COVID cognitve complaints, and/or medical diagnoses affecting cognitive function

Primary outcomes:
measure: Cognigram(R)
timeFrame: 12-months
Secondary outcomes:
measure: Montreal Cognitive Assessment
timeFrame: 12-months
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: University of Alberta
state: Alberta
Study officials:
References:
Clinical trial NCT05222048: Endoscopy Needs of People in Suichang County, Lishui City, Zhejiang Province, China
Official title: Endoscopy Needs of People in Suichang County
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Gastrointestinal Endoscopy
Keywords: Gastrointestinal endoscopy, demand analysis,
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2022-02-03
Enrollment: 1061
Sex: ALL
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Permanent resident population above 14 years old in Suichang County, excluding foreign nationals.

Brief summary: With the improvement of people's health awareness, more and more people realize the importance of endoscopy. Compared with other imaging methods (such as gastrointestinal contrast, abdominal ultrasound, CT, MR, nuclear medicine, etc.), in addition to the diagnosis of diseases, endoscopy also has obvious advantages in obtaining specimens for further pathological examination. However, the pain and discomfort caused by endoscopy have discouraged many people and even missed the opportunity for early diagnosis. At present, painless endoscopy can improve this kind of situation, but everyone has various doubts about it. In order to accurately understand and grasp the needs of people in Suichang County for gastrointestinal endoscopy, so as to better carry out gastrointestinal endoscopy/screening/diagnosis and treatment work in the future, we designed this demand survey.


Eligibility criteria: Inclusion Criteria:

* All people who come to the endoscopy center for gastrointestinal endoscopy, as well as those who may have gastrointestinal endoscopy in outpatient clinics, ward patients and other social groups, and are willing to participate in the questionnaire survey.

Exclusion Criteria:

* People who cannot cooperate, are unconscious, or who are unwilling to participate in questionnaire surveys.

Primary outcomes:
measure: Individual choice of anesthesia during gastrointestinal endoscopy
timeFrame: 1 day
Secondary outcomes:
measure: Individual attitude towards gastrointestinal endoscopy follow-up
timeFrame: 1 day
Other outcomes:
Locations:
city: Lishui
country: China
facility: Department of Gastroenterology, Suichang People's Hospital
state: Zhejiang
Study officials:
References:
Clinical trial NCT02137148: Sonic Window Study Evaluation Plan
Official title: Observational Study of the Sonic Window Handheld Ultrasound System for Assistance With Vascular Access and Needle Placement
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Non-palpable Veins
Keywords: Vascular Access
Sonic Window
Ultrasound
Lead sponsor: Analogic Corporation
Sponsor class: INDUSTRY
First posted: 2014-05-13
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 50 adults who require vascular access

Brief summary: The goals of this study are as follows; evaluation of the products' readiness to market, ascertain initial reactions by target users, evaluate actual use in potential clinical settings and any difficulties encountered with product use and actual venous cannulation.

Detailed description: This study was cancelled

Eligibility criteria: Inclusion Criteria:

* Patient Requires needle placement

Exclusion Criteria:

* Under 18 years of age
* Needle placement not required.

Primary outcomes:
measure: First Stick Success
timeFrame: 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Englewood
country: United States
facility: Englewood Hospital & Medical Center
state: New Jersey
Study officials:
affiliation: EHMC
name: Arveh Shander, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04828148: Incidence of Infection and Mortality by COVID-19 in Specialists
Official title: Incidence of Infection and Mortality by COVID-19 in Specialists in Mexico: A Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Health Care Associated Infection
Infection, Coronavirus
Death
Lead sponsor: Instituto Mexicano del Seguro Social
Sponsor class: OTHER_GOV
First posted: 2021-04-01
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Active physicians and medical students who have had contact with COVID-19 patients.

Brief summary: In this current study the researchers aim to identify the total number of infections and deaths due to COVID-19 and distinguish which are the risk factors most related to COVID-19 infections and deaths in medical personnel in Mexico.


Eligibility criteria: Inclusion Criteria:

* Active physicians and medical students who have had contact with patients infected by COVID-19
* Active physicians and medical students who have been infected by COVID-19

Exclusion Criteria:

* Members of the general population
* Inactive physicians or medical students
* Incomplete surveys

Primary outcomes:
measure: Incidence of mortality in physicians due to COVID-19
timeFrame: Baseline
measure: Incidence of infection in physicians due to COVID-19
timeFrame: Baseline
Secondary outcomes:
measure: Physician´s Risk factors of contagion such as age, gender, medical degree, and comorbidities
timeFrame: Baseline
Other outcomes:
Locations:
city: Guadalajara
country: Mexico
facility: Centro Médico Nacional de Occidente
state: Jalisco
Study officials:
References:
Clinical trial NCT02924948: A Comparison of Endoscopic Ultrasound Insertion Methods
Official title: A Comparison of Endoscopic Ultrasound Insertion Methods: Conventional vs Inflated Balloon Method
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Throat Pain After EUS Insertion
Keywords: Endoscopic ultrasonography
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2016-10-05
Enrollment: 482
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Endoscopic ultrasonography (EUS) is an essential technique required in diagnosis of pancreatobiliary diseases. In previous studies, 6% of patients who undergone EUS had significant throat pain. (NRS scale 5 or greater) Although some endoscopists think balloon inflation while EUS insertion could result in decreased throat damage and pain, there is no data to back up. We designed a single center randomized pilot study to compare throat pain caused by EUS insertion with conventional vs balloon inflation method.

Detailed description: All patients who are undergoing EUS with radial type echoendoscope will be asked for an informed consent. Subjects will be randomized to conventional insertion arm and balloon inflated insertion arm. All patients will be sedated according to SNUH endoscopy center protocol. Conventional insertion will be done in conventional insertion group, and balloon inflation before the start of procedure will be done in balloon inflated insertion arm. After the EUS procedure is finished, subject will be moved to a recovery room. As soon as the subject is recovered from sedation, throat pain will be assessed in NRS scale and be recoreded. Information of insertion failure and balloon damage during insertion will be also collected.

Eligibility criteria: Inclusion Criteria:

* Patients aged from 20 to 80
* Patients undergoing EUS with radial echoendoscope

Exclusion Criteria:

* Refuse to participate the study
* Refuse EUS procedure

Primary outcomes:
measure: Throat pain
timeFrame: Assess right after the end of the EUS procedure
Secondary outcomes:
measure: Throat pain intensity
timeFrame: Assess right after the end of the EUS procedure
measure: EUS Insertion failure rate
timeFrame: Right after insertion
measure: Damaged balloon rate
timeFrame: during EUS procedure
Other outcomes:
Locations:
Study officials:
affiliation: Seoul National University Hospital
name: Sang Hyub Lee, MD. PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02246348: Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
Official title: Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Systemic Sclerosis
Pulmonary Hypertension
Keywords: Systemic Sclerosis
Pulmonary hypertension
Lung Doppler signals
Lead sponsor: Echosense Ltd.
Sponsor class: INDUSTRY
First posted: 2014-09-22
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package; i.e. the transthoracic parametric Doppler (TPD) (EchoSense Ltd., Haifa, Israel). Systemic sclerosis patients often develop pulmonary vascular disease leading to pulmonary hypertension. The TPD system may provide important insight into pulmonary blood vessels characteristics by the LDS signals that are related to pulmonary hypertension.

The TPD performance in detecting PAH in SSc patients will be assessed in the study.


Eligibility criteria: Inclusion Criteria:

1. Able and willing to give signed informed consent prior to enrollment
2. Male or female, ≥ 18 years of age
3. Diagnosis of SSc according to 2013 ACR/EULAR SSc Classification Criteria (van den Hoogen 2013): Score ≥ 9.
4. Patients with RHC data available from measurement within 3 weeks prior to TPD assessment
5. No change in or initiation of PAH specific therapy between the last RHC and TPD

Exclusion Criteria:

1. People unable or unwilling to give informed consent.
2. PCWP or LVEDP \> 15 mmHg
3. Any PH etiology outside Group 1 (Dana Point, 2008)
4. Pregnant women
5. Patients having severe chest wall deformity

Primary outcomes:
measure: Number of SSc patients correctly identified with pulmonary hypertension severity in each of the 4 defined groups by RHC.
timeFrame: 12 month
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Reumatology department, Rambam medical center
Study officials:
affiliation: Rambam Health Care Campus
name: Alexsandra Balbir, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04747548: Inhibitory Control and Pediatric Weight Management
Official title: Supplementing Evidence-based Commercial Weight Management Program With Inhibitory Control Training in Youth: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Overweight and Obesity
Lead sponsor: Cedars-Sinai Medical Center
Sponsor class: OTHER
Collaborators: name: University of California, Riverside
First posted: 2021-02-10
Enrollment: 21
Sex: ALL
Minimum age (years): 7
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this pilot study is to explore the benefits of supplementing the Kurbo online program with a cognitive training game (PolyRules!) among youth ages 7-13 with overweight or obesity.


Eligibility criteria: Inclusion Criteria:

* Between 7-13 years old at time of enrollment
* Are able to read, write and speak English
* BMI%ile ≥ 85%ile

Exclusion Criteria:

* Concurrently enrolled in another weight loss intervention, are currently taking anti-obesity medications, or are undergoing bariatric surgery
* Have type 1 or type 2 diabetes
* Have severe cognitive delays
* Have visual/hearing impairments

Primary outcomes:
measure: Change in BMI from baseline to 3 months to yield effect size.
timeFrame: Baseline, 1 month
Secondary outcomes:
measure: Improvement in self-reported diet based on adherence to dietary guidelines.
timeFrame: Baseline, 1 month
measure: Improvement in self-reported physical activity based on adherence to physical activity guidelines.
timeFrame: Baseline, 1 month
measure: Change in performance on the cancellation task.
timeFrame: Baseline, 1 month
measure: Change in performance on the countermanding task.
timeFrame: Baseline, 1 month
measure: Change in performance on the N-back task.
timeFrame: Baseline, 1 month
measure: Change in performance on the letter-number task.
timeFrame: Baseline, 1 month
measure: Change in visuo-spatial working memory based on performance on the Corsi task.
timeFrame: Baseline, 1 month
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Cedars-Sinai Medical Center
state: California
Study officials:
affiliation: Cedars-Sinai Medical Center
name: Sarah-Jeanne Salvy, PhD
role: PRINCIPAL_INVESTIGATOR
References: